These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 3734795)
41. Monoamine oxidase-catalyzed metabolism of 3,4-dihydroxyphenylethylamine in the dopaminergic synaptosomes from rat corpus striatum. Katz IR J Neurochem; 1982 Mar; 38(3):859-62. PubMed ID: 7057199 [TBL] [Abstract][Full Text] [Related]
42. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Garrick NA; Murphy DL Psychopharmacology (Berl); 1980; 72(1):27-33. PubMed ID: 6781004 [No Abstract] [Full Text] [Related]
43. Localization of rat striatal monoamine oxidase activities towards dopamine, serotonin and kynuramine by gradient centrifugation and nigro-striatal lesions. Van der Krogt JA; Koot-Gronsveld E; Van den Berg CJ Life Sci; 1983 Aug; 33(7):615-23. PubMed ID: 6877035 [TBL] [Abstract][Full Text] [Related]
44. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Youdim MB; Weinstock M Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899 [TBL] [Abstract][Full Text] [Related]
45. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A. Finberg JP Acta Psychiatr Scand Suppl; 1995; 386():8-13. PubMed ID: 7717096 [TBL] [Abstract][Full Text] [Related]
46. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694 [TBL] [Abstract][Full Text] [Related]
47. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. Butcher SP; Fairbrother IS; Kelly JS; Arbuthnott GW J Neurochem; 1990 Sep; 55(3):981-8. PubMed ID: 2117053 [TBL] [Abstract][Full Text] [Related]
48. Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium. Lenzen S; Nahrstedt H; Panten U Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov; 324(3):190-5. PubMed ID: 6419132 [TBL] [Abstract][Full Text] [Related]
49. Characteristics of mitochondrial and synaptosomal monoamine oxidase in monkey brain. Egashira T; Yamamoto T; Yamanaka Y Jpn J Pharmacol; 1984 Feb; 34(2):211-9. PubMed ID: 6431160 [TBL] [Abstract][Full Text] [Related]
50. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Green AR; Mitchell BD; Tordoff AF; Youdim MB Br J Pharmacol; 1977 Jul; 60(3):343-9. PubMed ID: 890205 [No Abstract] [Full Text] [Related]
51. Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors. Yu PH; Davis BA; Durden DA; Barber A; Terleckyj I; Nicklas WG; Boulton AA J Neurochem; 1994 Feb; 62(2):697-704. PubMed ID: 8294932 [TBL] [Abstract][Full Text] [Related]
52. [Properties of intestinal monoamine oxidase in the rat]. Verevkina IV; Asnina VV; Gorkin VZ Vopr Med Khim; 1982; 28(2):88-93. PubMed ID: 7080482 [TBL] [Abstract][Full Text] [Related]
53. Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain. Nguyen TB; Angers M Biochem Pharmacol; 1987 May; 36(10):1731-5. PubMed ID: 3109430 [TBL] [Abstract][Full Text] [Related]
54. [Effect of solubilization by methylethylketone of rat liver mitochondrial monoamine oxidase on inhibition by clorgyline and deprenyl of the enzyme activity]. Severina IS; Klimova GI; Nersisian AA Biokhimiia; 1981 Nov; 46(11):2043-55. PubMed ID: 6797482 [TBL] [Abstract][Full Text] [Related]
55. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway. Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254 [TBL] [Abstract][Full Text] [Related]
56. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Gal S; Abassi ZA; Youdim MB Neurotox Res; 2010 Aug; 18(2):143-50. PubMed ID: 19894083 [TBL] [Abstract][Full Text] [Related]
57. Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. Fowler CJ; Tipton KF J Neurochem; 1982 Mar; 38(3):733-6. PubMed ID: 7057191 [TBL] [Abstract][Full Text] [Related]
58. Effects of acute and repeated administration of amiflamine on monoamine oxidase inhibition in the rat. Ask AL; Fagervall I; Jonze M; Kelder D; Nygren R; Ross SB Biochem Pharmacol; 1984 Sep; 33(18):2839-47. PubMed ID: 6477643 [TBL] [Abstract][Full Text] [Related]
59. [Mechanism of inhibition by chlorgyline and deprenyl of tyramine deamination by mitochondrial monoamine oxidase of rat liver]. Deverina IS Biokhimiia; 1980 Oct; 45(10):1897-908. PubMed ID: 6786369 [TBL] [Abstract][Full Text] [Related]